Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug:81:116-129.
doi: 10.1016/j.ejca.2017.01.035. Epub 2017 Jun 15.

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

Leisha A Emens  1 , Paolo A Ascierto  2 , Phillip K Darcy  3 , Sandra Demaria  4 , Alexander M M Eggermont  5 , William L Redmond  6 , Barbara Seliger  7 , Francesco M Marincola  8
Affiliations
Review

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

Leisha A Emens et al. Eur J Cancer. 2017 Aug.

Abstract

Cancer immunotherapy is now established as a powerful way to treat cancer. The recent clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) highlights both the universal power of treating the immune system across tumour types and the unique features of cancer immunotherapy. Immune-related adverse events, atypical clinical response patterns, durable responses, and clear overall survival benefit distinguish cancer immunotherapy from cytotoxic cancer therapy. Combination immunotherapies that transform non-responders to responders are under rapid development. Current challenges facing the field include incorporating immunotherapy into adjuvant and neoadjuvant cancer therapy, refining dose, schedule and duration of treatment and developing novel surrogate endpoints that accurately capture overall survival benefit early in treatment. As the field rapidly evolves, we must prioritise the development of biomarkers to guide the use of immunotherapies in the most appropriate patients. Immunotherapy is already transforming cancer from a death sentence to a chronic disease for some patients. By making smart, evidence-based decisions in developing next generation immunotherapies, cancer should become an imminently treatable, curable and even preventable disease.

Keywords: Cancer immunotherapy; Cytotoxic T lymphocyte antigen-4 (CTLA-4); Immune checkpoint blockade; Programmed death ligand-1 (PD-L1); Programmed death-1 (PD-1); Tumour immunity.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms